229 results on '"Friberg, Lena E"'
Search Results
2. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children
3. Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework
4. Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
5. Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model
6. Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis
7. Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model
8. Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli
9. Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue– Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations
10. Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia
11. Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
12. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
13. Predicting the Long‐Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis.
14. Integration of individual preclinical and clinical anti‐infective PKPD data to predict clinical study outcomes.
15. Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice
16. Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib.
17. Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections
18. Considerations for the optimal management of antibiotic therapy in elderly patients
19. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes
20. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy
21. Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
22. Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection
23. Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time–kill experiments: agreement with in silico predictions.
24. Multistate modeling for survival analysis in critically ill patients treated with meropenem.
25. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
26. Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies.
27. A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology.
28. A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer.
29. Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models.
30. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
31. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
32. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling
33. Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the IMpower131 Study.
34. A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory
35. Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs
36. Inter occasion variability in individual optimal design
37. Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.
38. Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors.
39. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients
40. Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout
41. Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling
42. A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
43. Bayesian forecasting of tumor size metrics and overall survival.
44. Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever.
45. Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose.
46. Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation.
47. Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
48. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS
49. A tool for neutrophil guided dose adaptation in chemotherapy
50. Dose response of whole-grain biomarkers: alkylresorcinols in human plasma and their metabolites in urine in relation to intake
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.